The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website; (3) the federal government Internet portal; or (4) a web search conducted using a commercial search engine such as
Accession Number ADA569964
Title Characterization and Targeting of the Aldehyde Dehydrogenase Subpopulation in Ovarian Cancer.
Publication Date Jul 2012
Media Count 54p
Personal Author J. C. Landen
Abstract Despite a common outstanding response to primary therapy, most ovarian cancer patients will experience recurrence due to what is often microscopic undetectable disease. One possible cause of this is a chemoresistant population of cells with stem cell characteristics. We have examined one potential population in particular, the ALDH-positive population. We have shown that ALDH1A1-positive cells are more tumorigenic than ALDH1A1- negative cells, contribute to poor patient outcomes, and contribute to chemoresistance. Importantly, these effects can be reversed by downregulating ALDH1A1 expression with nanoparticle-delivered siRNA. Additionally, we have shown that CSCs are clinically significant, in that chemoresistant tumors have increased density of ALDH and CD133 cells. Thus they likely represent at least part of the chemoresistant population within a heterogeneous tumor. Importantly, they do not seem to explain the entire story, as there are still many CSC-negative cells present at the conclusion of treatment. Additional studies will be performed to determine which other cell types may be present in chemoresistant tumors, and which pathways or mechanisms may be mediating this resistance.
Keywords Aldehydes
In vivo analysis
Ovarian cancer
Stem cells

Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
Corporate Author Alabama Univ. in Birmingham.
Document Type Technical report
Title Note Annual rept. 1 Jul 2011-30 Jun 2012.
NTIS Issue Number 1314
Contract Number W81XWH-10-1-0461

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader